

Underpowered or negative? A crucial distinction.

Citation for published version (APA):

Connell, N. J., Houtkooper, R. H., & Schrauwen, P. (2019). Underpowered or negative? A crucial distinction. Reply to Dollerup OL, Treebak JT, Jessen N [letter]. *Diabetologia*, 62(6), 1096-1096. <https://doi.org/10.1007/s00125-019-4868-3>

Document status and date:

Published: 01/06/2019

DOI:

[10.1007/s00125-019-4868-3](https://doi.org/10.1007/s00125-019-4868-3)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.



Underpowered or negative? A crucial distinction. Reply to Dollerup OL, Treebak JT, Jessen N [letter]

Niels J. Connell¹ · Riekelt H. Houtkooper² · Patrick Schrauwen¹

Received: 13 March 2019 / Accepted: 13 March 2019 / Published online: 13 April 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Keywords Clinical trial · Human · NAD⁺ metabolism

To the Editor: Jessen and colleagues [1] have commented on our recent review of NAD⁺ metabolism in *Diabetologia* [2]. In their letter, they comment on the discussion and citation of a clinical trial that they performed, in which dietary nicotinamide riboside was supplemented in obese men to assess the effects on whole body insulin sensitivity [3].

We concede to the argument made by Jessen and colleagues that it is important to make a clear distinction between endpoints when citing clinical trials, as this may otherwise lead to unwanted assumptions regarding the endpoint(s) that are discussed. In our review, we did not have the intention to suggest that the study by Dollerup et al [3] was underpowered for its primary endpoint, insulin sensitivity, but unfortunately omitted to add ‘for these secondary endpoints’, for which we do apologise. Nevertheless, the overall message and conclusion of our review does not change and we agree with Jessen and colleagues that more human studies are needed to test the efficacy of dietary supplements in rigorously designed human clinical trials.

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.

References

1. Dollerup OL, Treebak JT, Jessen N (2019) Underpowered or negative? A crucial distinction. *Diabetologia*. <https://doi.org/10.1007/s00125-019-4853-x>
2. Connell NJ, Houtkooper RH, Schrauwen P (2019) NAD⁺ metabolism as a target for metabolic health: have we found the silver bullet? *Diabetologia*. <https://doi.org/10.1007/s00125-019-4831-3>
3. Dollerup OL, Christensen B, Svart M et al (2018) A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. *Am J Clin Nutr* 108(2):343–353. <https://doi.org/10.1093/ajcn/nqy132>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Patrick Schrauwen
p.schrauwen@maastrichtuniversity.nl

¹ Department of Nutrition and Movement Sciences, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Universiteitssingel 50, P.O. Box 616, 6200 MD Maastricht, the Netherlands

² Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands